Guggenheim Maintains Buy on Lowe's Companies, Lowers Price Target to $275
Guggenheim analyst Steven Forbes maintains Lowe's Companies (NYSE:LOW) with a Buy and lowers the price target from $300 to $275.
Read original at benzingaStocks · News reference
TNON: 110% | Tenon Medical shares are trading higher after the company received a notice of allowance for a U.S. Patent Titled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints" LZB: -18% |
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim analyst Steven Forbes maintains Lowe's Companies (NYSE:LOW) with a Buy and lowers the price target from $300 to $275.
Read original at benzingaTelsey Advisory Group analyst Joseph Feldman maintains Lowe's Companies (NYSE:LOW) with a Outperform and lowers the price target from $280 to $260.
Read original at benzingaCitigroup analyst Steven Zaccone maintains Lowe's Companies (NYSE:LOW) with a Buy and lowers the price target from $267 to $260.
Read original at benzingaTruist Securities analyst Scot Ciccarelli maintains Lowe's Companies (NYSE:LOW) with a Buy and lowers the price target from $255 to $254.
Read original at benzingaKeybanc analyst Bradley B. Thomas maintains La-Z-Boy (NYSE:LZB) with a Overweight and lowers the price target from $46 to $40.
Read original at benzingaLa-Z-Boy (NYSE:LZB) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Read original at benzinga